Exelixis, Inc. or ImmunityBio, Inc.: Who Invests More in Innovation?

Exelixis leads in R&D investment over ImmunityBio by a wide margin.

__timestampExelixis, Inc.ImmunityBio, Inc.
Wednesday, January 1, 20141891010001595000
Thursday, January 1, 20159635100011434000
Friday, January 1, 20169596700026546000
Sunday, January 1, 201711217100039778000
Monday, January 1, 201818225700053418000
Tuesday, January 1, 2019336964000111997000
Wednesday, January 1, 2020547851000139507000
Friday, January 1, 2021693716000195958000
Saturday, January 1, 2022891813000248149000
Sunday, January 1, 20231044071000232366000
Monday, January 1, 2024910408000
Loading chart...

Igniting the spark of knowledge

Innovation Investment: Exelixis vs. ImmunityBio

In the competitive landscape of biotechnology, innovation is the lifeblood of success. Over the past decade, Exelixis, Inc. and ImmunityBio, Inc. have been at the forefront of this race, investing heavily in research and development (R&D) to drive breakthroughs. From 2014 to 2023, Exelixis has consistently outpaced ImmunityBio in R&D spending, with a staggering 450% increase, peaking at over $1 billion in 2023. In contrast, ImmunityBio's investment grew by approximately 145% during the same period, reaching around $232 million.

This significant disparity highlights Exelixis's aggressive strategy to maintain its competitive edge. The data underscores the importance of sustained investment in R&D for biotech companies aiming to lead in innovation. As the industry evolves, these investments will likely play a crucial role in shaping the future of healthcare and treatment options.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025